Literature DB >> 16237462

RNAi: a potential therapy for the dominantly inherited nucleotide repeat diseases.

E M Denovan-Wright1, B L Davidson.   

Abstract

Genetic diseases that are accompanied by central nervous system involvement are often fatal. Among these are the autosomal dominant neurogenetic diseases caused by nucleotide repeat expansion. For example, Huntington's disease (HD) and spinal cerebellar ataxia are caused by expansion of a tract of CAGs encoding glutamine. In HD and the other CAG-repeat expansion diseases, the expansion is in the coding region. Myotonic dystrophy is caused by repeat expansions of CUG or CCTG in noncoding regions, and the mutant RNA is disease causing. Treatments for these disorders are limited to symptomatic intervention. RNA interference (RNAi), which is a method for inhibiting target gene expression, provides a unique tool for therapy by attacking the fundamental problem directly. In this review, we describe briefly several representative disorders and their respective molecular targets, and methods to accomplish therapeutic RNAi. Finally, we summarize studies performed to date. Gene Therapy (2006) 13, 525-531. doi:10.1038/sj.gt.3302664; published online 20 October 2005.

Entities:  

Mesh:

Year:  2006        PMID: 16237462     DOI: 10.1038/sj.gt.3302664

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  14 in total

1.  Investigation of RNA interference to suppress expression of full-length and fragment human huntingtin.

Authors:  Devin S Gary; Abigail Davidson; Olivier Milhavet; Hilda Slunt; David R Borchelt
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

Review 2.  New developments in RAN translation: insights from multiple diseases.

Authors:  John Douglas Cleary; Laura Pw Ranum
Journal:  Curr Opin Genet Dev       Date:  2017-03-30       Impact factor: 5.578

3.  RNA interference-based therapeutics for inherited long QT syndrome.

Authors:  Guoliang Li; Shuting Ma; Chaofeng Sun
Journal:  Exp Ther Med       Date:  2015-06-12       Impact factor: 2.447

Review 4.  RNAi: a potential new class of therapeutic for human genetic disease.

Authors:  Attila A Seyhan
Journal:  Hum Genet       Date:  2011-05-03       Impact factor: 4.132

5.  Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs.

Authors:  Jiaxin Hu; Keith T Gagnon; Jing Liu; Jonathan K Watts; Jeja Syeda-Nawaz; C Frank Bennett; Eric E Swayze; John Randolph; Jyoti Chattopadhyaya; David R Corey
Journal:  Biol Chem       Date:  2011-02-07       Impact factor: 3.915

6.  Experimental models for identifying modifiers of polyglutamine-induced aggregation and neurodegeneration.

Authors:  Barbara Calamini; Donald C Lo; Linda S Kaltenbach
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

7.  Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA.

Authors:  Jiaxin Hu; Masayuki Matsui; David R Corey
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

Review 8.  Neuroprotection for Huntington's disease: ready, set, slow.

Authors:  Steven M Hersch; H Diana Rosas
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

9.  Molecular Effects of the CTG Repeats in Mutant Dystrophia Myotonica Protein Kinase Gene.

Authors:  Beatriz Llamusí; Ruben Artero
Journal:  Curr Genomics       Date:  2008-12       Impact factor: 2.236

10.  Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs.

Authors:  Jiaxin Hu; Masayuki Matsui; Keith T Gagnon; Jacob C Schwartz; Sylvie Gabillet; Khalil Arar; Jun Wu; Ilya Bezprozvanny; David R Corey
Journal:  Nat Biotechnol       Date:  2009-05-03       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.